Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 319

1.

Factors associated with the initiation of disease-modifying antirheumatic drugs in newly diagnosed rheumatoid arthritis: a retrospective claims database study.

Bonafede MM, Fox KM, Johnson BH, Watson C, Gandra SR.

Clin Ther. 2012 Feb;34(2):457-67. doi: 10.1016/j.clinthera.2011.12.016. Epub 2012 Jan 28.

PMID:
22284901
2.

Predictors of treatment initiation with tumor necrosis factor-α inhibitors in patients with rheumatoid arthritis.

Desai RJ, Rao JK, Hansen RA, Fang G, Maciejewski ML, Farley JF.

J Manag Care Spec Pharm. 2014 Nov;20(11):1110-20.

3.

Treatment of older adult patients diagnosed with rheumatoid arthritis: improved but not optimal.

Schmajuk G, Schneeweiss S, Katz JN, Weinblatt ME, Setoguchi S, Avorn J, Levin R, Solomon DH.

Arthritis Rheum. 2007 Aug 15;57(6):928-34.

4.
6.
7.

Medical resource use and costs among rheumatoid arthritis patients receiving disease-modifying antirheumatic drug therapy.

Griffiths RI, Bar-Din M, MacLean CH, Sullivan EM, Herbert RJ, Yelin EH.

Arthritis Care Res. 2000 Aug;13(4):213-26.

8.

Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.

Pelletier EM, Ogale S, Yu E, Brunetta P, Garg J.

Clin Ther. 2009 Nov;31(11):2653-64. doi: 10.1016/j.clinthera.2009.11.032.

PMID:
20110008
9.

Therapeutic strategies in rheumatoid arthritis over a 40-year period.

Kremers HM, Nicola P, Crowson CS, O'Fallon WM, Gabriel SE.

J Rheumatol. 2004 Dec;31(12):2366-73.

PMID:
15570636
11.

Patterns of disease-modifying antirheumatic drug use, medical resource consumption, and cost among rheumatoid arthritis patients.

Griffiths RI, Bar-Din M, MacLean C, Sullivan EM, Herbert RJ, Yelin EH.

Ther Apher. 2001 Apr;5(2):92-104.

PMID:
11354305
12.

Patterns of drug use in rheumatoid arthritis.

Bérard A, Solomon DH, Avorn J.

J Rheumatol. 2000 Jul;27(7):1648-55.

PMID:
10914846
13.

The changing use of disease-modifying anti-rheumatic drugs in individuals with rheumatoid arthritis from the United Kingdom General Practice Research Database.

Edwards CJ, Arden NK, Fisher D, Saperia JC, Reading I, Van Staa TP, Cooper C.

Rheumatology (Oxford). 2005 Nov;44(11):1394-8. Epub 2005 Jul 19.

14.

Biologic disease-modifying drug treatment patterns and associated costs for patients with rheumatoid Arthritis.

McBride S, Sarsour K, White LA, Nelson DR, Chawla AJ, Johnston JA.

J Rheumatol. 2011 Oct;38(10):2141-9. doi: 10.3899/jrheum.101195. Epub 2011 Aug 15.

PMID:
21844154
15.
16.

Lag time between onset of symptoms and access to rheumatology care and DMARD therapy in a cohort of patients with rheumatoid arthritis.

Hernández-García C, Vargas E, Abásolo L, Lajas C, Bellajdell B, Morado IC, Macarrón P, Pato E, Fernández-Gutiérrez B, Bañares A, Jover JA.

J Rheumatol. 2000 Oct;27(10):2323-8.

PMID:
11036824
17.

Receipt of disease-modifying antirheumatic drugs among patients with rheumatoid arthritis in Medicare managed care plans.

Schmajuk G, Trivedi AN, Solomon DH, Yelin E, Trupin L, Chakravarty EF, Yazdany J.

JAMA. 2011 Feb 2;305(5):480-6. doi: 10.1001/jama.2011.67.

19.

Utilization patterns of disease-modifying antirheumatic drugs in elderly rheumatoid arthritis patients.

Jin XM, Lee J, Choi NK, Seong JM, Shin JY, Kim YJ, Kim MS, Yang BR, Park BJ.

J Korean Med Sci. 2014 Feb;29(2):210-6. doi: 10.3346/jkms.2014.29.2.210. Epub 2014 Jan 28.

20.
Items per page

Supplemental Content

Write to the Help Desk